Get started

ETF market

10 Small-Cap Biotechs with Key Catalysts for 2025 July List________________________________________ 🔬 10 Small-Cap Biotechs with Key Catalysts for 2025 July List ________________________________________ 1. Allogene Therapeutics (NASDAQ: ALLO) • Catalyst: Phase 2 data for ALLO-501A (anti-CD19 CAR-T for large B-cell lymphoma) expected in H2 2025; potential pivotal data could lead to regulatory submission. • Highlights: “Off-the-shelf” allogeneic CAR-T approach could transform cell therapy; watch for manufacturing/scalability updates. ________________________________________ 2. Lixte Biotechnology (NASDAQ: LIXT) • Catalyst: Phase 2 combo trial of LB-100 (PP2A inhibitor) + immunotherapy in solid tumors, with key data expected in late 2025. • Highlights: If efficacy signals emerge, could prompt partnerships or additional trials. ________________________________________ 3. Iovance Biotherapeutics (NASDAQ: IOVA) • Catalyst: Commercial launch and sales uptake for AMTAGVI (lifileucel, first FDA-approved TIL therapy in advanced melanoma); upcoming label expansion studies in lung and cervical cancer. • Highlights: Investor focus on launch ramp, real-world data, and new trial initiations in 2025. ________________________________________ 4. RenBio (NASDAQ: RENB) • Catalyst: Phase 1/2 data for RB-100 (bispecific antibody platform in solid tumors) expected mid-to-late 2025. • Highlights: Pipeline progress and partnership announcements possible. ________________________________________ 5. IGM Biosciences (NASDAQ: IGMS) • Catalyst: Phase 2 data for IGM-2323 (CD20 x CD3 bispecific in non-Hodgkin lymphoma) expected early 2025; ongoing updates from IgM antibody platform. • Highlights: Investor interest in clinical safety, efficacy, and potential for big pharma tie-ups. ________________________________________ 6. Zura Bio (NASDAQ: ZURA) • Catalyst: Phase 2b/3 trial start and topline data for tibulizumab (IL-7Ra mAb for autoimmune diseases) expected late 2025. • Highlights: Focus on rare and orphan autoimmune indications. ________________________________________ 7. INmune Bio (NASDAQ: INMB) • Catalyst: Phase 2 Alzheimer’s data (XPro1595, targeting neuroinflammation) and oncology pipeline updates expected H1 2025. • Highlights: Any signal in Alzheimer’s is high-impact; monitoring for FDA guidance. ________________________________________ 8. Veru Inc (NASDAQ: VERU) • Catalyst: Phase 3 trial results for enobosarm (oral SARM) in advanced breast cancer expected 2025; also, COVID/sepsis drug updates. • Highlights: Regulatory clarity and partnership/M&A rumors are potential drivers. ________________________________________ 9. Century Therapeutics (NASDAQ: IPSC) • Catalyst: First-in-human data for iPSC-derived NK and CAR-T cell therapies, with updates expected at major meetings in 2025. • Highlights: Platform validation and early efficacy/safety signals. ________________________________________ 10. ProKidney (NASDAQ: PROK) • Catalyst: Phase 3 pivotal data for REACT (cell therapy for chronic kidney disease/diabetes) due late 2025. • Highlights: If positive, could become the first autologous cell therapy for kidney disease. ________________________________________ 🔎 How to Monitor These Catalysts • FDA submissions/meetings (ALLO, PROK, VERU) • Clinical trial readouts (LIXT, RENB, IGMS, ZURA, INMB, IPSC) • Commercial/launch data (IOVA) • Partnership/M&A activity (IGMS, VERU, RENB) ________________________________________ 📊 Summary Table Ticker Company Upcoming Catalyst/Event Timeframe ALLO Allogene Therapeutics Phase 2 LBCL CAR-T pivotal data H2 2025 LIXT Lixte Biotechnology LB-100 + immunotherapy Phase 2 data Late 2025 IOVA Iovance Biotherapeutics AMTAGVI launch data; label expansions Throughout 2025 RENB RenBio Bispecifics Phase 1/2 data Mid-to-late 2025 IGMS IGM Biosciences IGM-2323 Phase 2 data (lymphoma) Early 2025 ZURA Zura Bio Tibulizumab Phase 2b/3 topline data Late 2025 INMB INmune Bio Alzheimer’s/oncology trial updates H1 2025 VERU Veru Inc Enobosarm Phase 3 (breast cancer) 2025 IPSC Century Therapeutics First-in-human iPSC cell therapy data 2025 PROK ProKidney REACT Phase 3 (CKD) pivotal readout Late 2025 ________________________________________ ⚠️ Word of Caution Small-cap biotech stocks can be extremely volatile, especially around catalyst events (trial data, FDA decisions). Sharp price swings—both up and down—are common. Always conduct your own research and be aware of the risks.
NASDAQ:IBBLong
by ProjectSyndicate
31
SPY/QQQ Plan Your Trade For 7-1 : Post Market UpdateToday was a very powerful day for the Cycle Patterns - particularly for Gold and BTCUSD. Gold rallied as the Cycle Pattern predicted a RALLY in TREND mode. BTCUSD collapsed on a CRUSH Cycle Pattern. The SPY Cycle Pattern predicted a Gap Reversal pattern. We did see the Gap today and a moderate reversal in price. But the SPY, as usual, continued to try to melt upward. I highlighted a very interesting TWINNING pattern in Bitcoin in this video. Pay attention. Get some. #trading #research #investing #tradingalgos #tradingsignals #cycles #fibonacci #elliotwave #modelingsystems #stocks #bitcoin #btcusd #cryptos #spy #gold #nq #investing #trading #spytrading #spymarket #tradingmarket #stockmarket #silver
AMEX:SPYLong
by BradMatheny
3
Nightly $SPY / $SPX Scenarios for July 2, 2025🔮 Nightly AMEX:SPY / SP:SPX Scenarios for July 2, 2025 🔮 🌍 Market-Moving News 🌍 🏭 U.S. Manufacturing Remains Under Pressure The ISM Manufacturing PMI for June rose slightly to 49.0 from 48.5 in May—still in contraction territory. Tariff-induced uncertainty and rising input costs continue to weigh on factory activity, with new orders still weak and employment contracting 📈 Global Factory Rebound Led by India & Europe While U.S. factories struggle, India hit a 14-month high in its manufacturing PMI at 58.4, and euro‑zone factory orders stabilized at 49.5—the first sign of recovery in over three years. Asia-Europe divergence may shift global capital flows . 🏦 Powell Says Tariffs Are Delaying Rate Cuts Fed Chair Powell warned at the ECB forum in Sintra that elevated inflation—driven in part by Trump-era tariffs—has postponed the timeline for U.S. rate cuts. The Fed’s dot-plot now indicates only two cuts for 2025, with markets adjusting accordingly 💵 Dollar Nears 3½-Year Lows The U.S. dollar weakened further, trading near a three-and-a-half-year low amid soft PMI data, a dovish Fed tilt, and renewed optimism over U.S.–Canada trade talks 📊 Key Data Releases & Events 📊 📅 Wednesday, July 2: (No major scheduled U.S. economic data) Market focus shifts to upcoming Nonfarm Payrolls on July 3, Powell's remarks, and trade-talk headlines. ⚠️ Disclaimer: This information is for educational and informational purposes only and should not be construed as financial advice. Always consult a licensed financial advisor before making investment decisions. 📌 #trading #stockmarket #economy #manufacturing #Fed #inflation #charting #technicalanalysis
AMEX:SPYShort
by TrendTao
How I screen for long term investmentsIn this video, I’ll show you the exact stock screener I use to find long-term investment opportunities — the kind of stocks you can buy and hold for years. I’ll walk you through the key metrics to look for, how to use free tools like TradingView screener, and what red flags to avoid. This strategy is perfect for beginner and experienced investors who want to build long-term wealth, not chase hype. Whether you're looking for undervalued stocks, consistent compounders, or just trying to build your long-term portfolio, this screener can help. Hope you enjoy!!
AMEX:SPYEducation
by MindOverMarket
nifty siver bees chart Nifty Silver BeES – RSI Strategy & Quick Analysis I wanted to share this Nifty Silver BeES chart with you all, purely for learning and discussion. By studying this chart, you might find some useful insights to sharpen your own analysis. One of the key things here is the RSI (Relative Strength Index) — it plays a major role in identifying potential entry and exit zones: ✅ Entry Zone: Whenever the RSI drops into the 30–35 range, it often signals a good buying opportunity. Historically, we tend to see a decent upward move from this zone. 🚩 Exit Zone: When the RSI approaches 70 or higher — especially near resistance levels — that’s usually a signal to start selling or at least tightening stops. That said, patience is absolutely crucial with this approach. Sometimes profit booking can take a while, and at other times, it could be as quick as “buy and get out.” It all depends on how the market behaves on that particular day. If you find this chart interesting, do let me know. And if you spot any ways to improve this strategy or add more depth to the analysis, I’d love to hear your thoughts! By the way, targeting a quick 2–4% profit often works quite well with this method, provided you stick to your plan and manage risk carefully.
NSE:SILVERBEES
by skg7777711
6/30/25 - $osol - $SOL is tokening stonks6/30/25 :: VROCKSTAR :: OTC:OSOL CRYPTOCAP:SOL is tokening stonks - so OTC:OSOL is osprey's SOL closed end fund - similar to OTC:OBTC that i talk about, the chart you see below is vs. the NAV e.g. this is currently at 17% discount to spot - and we know SOL will have an ETF this month - we see stocks being now tokenized on chain and SOL is the chain that will see the most volume - so if you like stable coins... you should like tokenized stocks even better - closed end funds trade funny V
OTC:OSOLLong
by VROCKSTAR
9
QQQ A Fall Expected! SELL! My dear subscribers, This is my opinion on the QQQ next move: The instrument tests an important psychological level 548.21 Bias - Bearish Technical Indicators: Supper Trend gives a precise Bearish signal, while Pivot Point HL predicts price changes and potential reversals in the market. Target - 535.27 About Used Indicators: On the subsequent day, trading above the pivot point is thought to indicate ongoing bullish sentiment, while trading below the pivot point indicates bearish sentiment. Disclosure: I am part of Trade Nation's Influencer program and receive a monthly fee for using their TradingView charts in my analysis. ——————————— WISH YOU ALL LUCK
NASDAQ:QQQShort
by AnabelSignals
4
QQQ Nasdaq 100 Year-End Price Target and Technical Rebound SetupIf you haven`t bought the previous oversold area on QQQ: Now the Nasdaq-100 ETF (QQQ), which tracks the performance of the largest non-financial companies in the Nasdaq, has recently entered oversold territory, suggesting that a technical rebound may be imminent. Similar to the Russell 2000, QQQ has experienced significant selling pressure, driving key technical indicators into oversold zones and creating favorable conditions for a bounce. The Relative Strength Index (RSI) has dropped below 30, a level that typically signals oversold conditions and the potential for a reversal. Additionally, QQQ is trading near key support levels, with a large portion of its components underperforming their 50-day and 200-day moving averages — a classic setup for a mean reversion rally. From a historical perspective, QQQ has shown a tendency to rebound strongly after similar oversold conditions, particularly when macroeconomic factors stabilize and buying pressure returns. Given the current technical setup, my price target for QQQ is $550 by the end of the year. This represents a recovery of approximately 8-10% from current levels, aligning with previous post-oversold rallies in the index. While downside risks remain — including potential volatility around Federal Reserve policy and broader economic data — the technical backdrop suggests that QQQ is well-positioned for a recovery in the coming months.
NASDAQ:QQQLong
by TopgOptions
2
SPY S&P 500 ETF Potential W-Shaped Recovery Forming We may be witnessing the formation of a W-shaped recovery on the SPY (S&P 500 ETF) – a classic double-bottom structure that often signals a strong reversal after a period of correction or volatility. Let’s dive into the technicals and what this could mean in the sessions ahead. 🔍 The Technical Setup: SPY recently tested key support around the $485-$500 zone, bouncing off that area twice in the past few weeks. This gives us the left leg of the W and the first bottom. After a modest relief rally to ~$520, we saw another pullback – but this second dip failed to break below the first bottom, a hallmark of the W-pattern. As of today, SPY is starting to reclaim ground toward the $517-$520 resistance zone. If bulls can push through this neckline area, especially with volume confirmation, we could see a breakout that targets the $530-$535 area in the short term. 🔑 Key Levels to Watch: Support: $490-$500 (double-bottom support zone) Neckline/Resistance: $530 Breakout Target: $550 (previous highs) Invalidation: A break below $490 with volume could invalidate the W-recovery idea and shift bias bearish. 📊 Momentum & Volume: RSI is climbing back above the 50 level – bullish momentum building. MACD shows a potential crossover forming, hinting at a shift in trend. Watch for increasing buy volume as SPY approaches the neckline – that’s where the bulls will need to step up. 🧠 Macro & Earnings Angle: Don’t forget – we’re entering a heavy earnings season and rate cut expectations are still a wildcard. A dovish tone from the Fed and strong corporate results could be the fuel that sends SPY higher to complete this W-shaped recovery. 🧭 Final Thoughts: This is a high-probability setup if neckline resistance is broken cleanly. Wait for confirmation before going heavy – fakeouts are common in double-bottom scenarios. If we do get the breakout, we may be looking at a broader market rebound going into summer. 🔔 Set alerts near $525. A confirmed breakout could mean the bulls are back in charge.
AMEX:SPYLong
by TopgOptions
Nightly $SPY / $SPX Scenarios for July 1, 2025 🔮 Nightly AMEX:SPY / SP:SPX Scenarios for July 1, 2025 🔮 🌍 Market-Moving News 🌍 📊 Core Inflation Edges Higher May’s core inflation rose unexpectedly to 2.7% year-over-year, up from 2.6%, casting uncertainty over the Fed’s timeline for rate cuts. While headline CPI sits at 2.3%, the resilience in underlying prices complicates policymakers’ projections for later this year 💵 Weak Dollar, Rising Rate-Cut Bets Markets are reacting to “summertime data”—like the core CPI uptick—with renewed optimism. Traders now see up to 75 bps in Fed rate cuts later this year, while the dollar remains near 3½-year lows on concerns about Powell’s independence and trade developments 🇨🇦 U.S.–Canada Trade Talks Resume Trade talks between the U.S. and Canada restarted today, following Ottawa’s suspension of its digital-services tax. Progress toward a broader agreement could reduce tariff risk and offer further relief to risk assets 📊 Key Data Releases & Events 📊 📅 Tuesday, July 1: All Day – U.S.–Canada Trade Talks Markets will watch for updates on tariff resolution and broader trade deals. Any breakthrough could notably boost equities and improve trade sentiment. 10:00 AM ET – ISM Manufacturing PMI (June) A below-50 reading again would reinforce the narrative of industrial weakness. A rebound could support equities and temper recession concerns 10:00 AM ET – JOLTS Job Openings (May) Still at elevated levels (~7.39 million in April), this metric assesses labor-market resilience. A decline could shift rate-cut expectations. ⚠️ Disclaimer: This is for educational and informational purposes only. It does not constitute financial advice. Consult a licensed financial advisor before investing. 📌 #trading #stockmarket #economy #news #trendtao #charting #technicalanalysis
AMEX:SPYShort
by TrendTao
The Big Banks are in BIG TROUBLEAs you can see on this weekly chart, the XLF has been in this steady up trend since October 2023. It bounced off this upward slopping trendline 3 different times and then finally broke through it on the 4th hit, then came back up to test the underside of the trendline as resistance. It did get back above the trendline briefly last month, but it ended up being a bull trap as it fell back below the trendline and is now testing it as resistance once again and is currently being rejected. A Fibonacci retrace shows the 0.786 fib level also lines up with this area giving added confluence, as well as RSI divergence that I have highlighted. Massive Massive resistance in this area and so much room for potential downside. I see this trade as an extremely high probability of playing out. The options market agrees with me as well.
AMEX:XLFShort
by bradc1984
Preponderance of (or Preposterous?) Evidence I was just proposing yesterday staying neutral in SPY (the S&P 500 ETF). The FOMC meeting today (Jun 18th) was a big-nothing burger (so far), which supports my (non)position, but we'll see. I will update that post when the time is right (ATH, 200dma, or bust). Today, though, the IWM (the Russell 2000 Small Cap Index ETF) and, surprisingly, a potential short position. First, the IWM (see below) is overbought on a weekly chart, with the Stochastics being above 80 (more on Stochastics and weekly charts at a later date). For now, let's go with IWM being a little overbought, in the longer-term view. Now, let's switch to the big daily chart at the top and look at the evidence for going short; - IWM never really got above it's 200-day moving average (purple line), - That same level was consistent with a lot of resistance ~213 (yellow circles), - IWM has trailed this whole rally. - It has broken and somewhat retested a trendline (light blue) from this most recent rally, - It bounced off it's 61.8% Fibonacci level (orange line, not my favorite indicator for ETFs, but I often sneak a peek), - It's at its previous resistance high around 209 (blue circles). On the not-bearish side; - The daily chart is less overbought (this has to happen on weakness, though), - There's (a little) support at 199 but not really again until 172, - I still feel like the All-Time-High (ATH) is a magnet for the S&P (but IWM has trailed). That's (a lot) more (and better) points for being bearish. I'll go short (via a ~90 day ITM put position*) if IWM breaks below 207.50, between that and 202. If it opens lower than 202, I'll wait for a pull-up. The stop will be a close above the 200 day. The target is 172 (the previous tariff low), but I will lighten/tighten up (by selling OTM puts* and/or moving stop down) as IWM drops (if it drops). It may seem a bit duplicitous to be neutral on SPY while being bearish on IWM. But sometimes you have to go with the Preponderance of Evidence (or will it prove Preposterous Evidence?) An update will be coming. *Sorry for bringing up options. One can just go short IWM. I will explain my option choice one day. My ideas here on TradingView are for educational purposes only. It is NOT trading advice. I often lose money and you would be a fool to follow me blindly.
AMEX:IWMShort
by TheUncertainTrader